BMY
USDBristol-Myers Squibb Company Common Stock
实时价格
价格图表
关键指标
市场指标
开盘价
$50.160
最高价
$50.740
最低价
$49.945
成交量
9.50M
公司基本面
市值
103.2B
所属行业
Drug Manufacturers - General
国家/地区
United States
交易统计
平均成交量
14.53M
交易所
NYQ
货币
USD
52周价格范围
相关新闻
BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals
German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
Bristol Myers Squibb (NYSE:BMY) will announce results for the second quarter of 2025 on Thursday, July 31, 2025. Company executives will review financial results with the investment community during a conference call
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland,
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated noninferiority in the
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
Bristol Myers Squibb (NYSE:BMY) today announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May 30-June 3
